A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector Device Versus Syringe in Patients With Multiple Sclerosis
Latest Information Update: 06 Apr 2026
At a glance
- Drugs Ublituximab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors TG Therapeutics Inc
Most Recent Events
- 06 Apr 2026 New trial record